NeurogesX’s Qutenza Potential For Successful Committee Review Hinges On Post Hoc Efficacy Analyses
This article was originally published in The Pink Sheet Daily
FDA looks askance at the sponsor’s post hoc analyses showing efficacy for its pain patch (capsaicin 8%) for HIV-associated neuropathic pain 30 minutes after application.
You may also be interested in...
The agency rejects the sponsor’s statistical analysis and says there is no statistically significant evidence of efficacy in the U.S. population, and the product seems likely to face a request for another trial from the advisory panel.
Gathering more data to assuage concerns about possibly lower efficacy in black patients will be key to converting the accelerated approval to full approval for the tuberculosis drug, FDA’s Anti-Infective Drugs Advisory Committee concludes.
Less than a year after signing a consent decree to resolve compliance problems, the company is forced to stop manufacturing its generic version of the best-selling cholesterol drug. For FDA, the issue poses a public relations challenge since it touches on several areas where the agency has recently been criticized – generic drug quality, manufacturing oversight and drug shortages.